Gang Xing

Gang joined Kojin in March 2022 as Associate Director, Molecular Pharmacology. Gang is responsible for developing Mass Spec-based technology platforms to enable biomarker discovery, mechanistic studies, compound target engagement, and cell-based compound screening. Gang comes to Kojin after 12 years working at Pfizer’s Internal Medicine Research Unit where he was responsible for developing the workflows associated with study design, sample prep, LC-MS analysis, and data interpretation supporting cell-based assay compound screening. He also played roles in animal model-based target engagement and biological mechanistic studies allowing for key insights to be discovered. These findings allowed for successful lead development candidates in Chemistry, precise drug dose prediction in both the preclinical and clinical settings, and clear guidance for CRO-based clinical target engagement studies. Prior to his industry career, Gang received his Ph.D. degree in Chemistry in Texas A&M University. Gang is an author for 20+ peer-reviewed publications from both industry and academia.